Clinical trials: WNT Pathway
Knee Osteoarthritis
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of…
- Trial name
- NCT03122860
- Testing
- SM04690
- Where
- 74 sites in United States
- Volunteers
- 700 people
- Sponsor
- Biosplice Therapeutics, Inc.
Endometrial Cancer, Uterine Cancer
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
- Conditions
- Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma
- Trial name
- P204 (NCT03395080)
- Testing
- Paclitaxel, 300mg DKN-01, 600mg DKN-01
- Where
- 17 sites in United States
- Volunteers
- 111 people
- Sponsor
- Leap Therapeutics, Inc.
Osteoarthritis of the Knee
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.
- Trial name
- NCT04931667
- Testing
- Lorecivivint
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis, Knee
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
Study OA-07 was a randomized, double-blind, placebo-controlled, Phase 3, multicenter, 2-year clinical trial that enrolled subjects from the recently completed Study OA-11 (NCT03928184).
- Trial name
- NCT04520607
- Testing
- Lorecivivint
- Where
- 42 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biosplice Therapeutics, Inc.
Knee Osteoarthritis
MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis
The purpose of this study was to evaluate the safety and efficacy of lorecivivint (LOR) injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.
- Trial name
- NCT03706521
- Testing
- lorecivivint
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biosplice Therapeutics, Inc.
Knee Osteoarthritis
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic…
- Trial name
- STRIDES-Xray (NCT03928184)
- Testing
- Lorecivivint
- Where
- 99 sites in United States
- Volunteers
- 501 people
- Sponsor
- Biosplice Therapeutics, Inc.
Knee Osteoarthritis
Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis…
- Trial name
- STRIDES-1 (NCT04385303)
- Testing
- Lorecivivint
- Where
- 76 sites in United States
- Volunteers
- 496 people
- Sponsor
- Biosplice Therapeutics, Inc.